FDA & CDC Recommend Pause in Johnson & Johnson (J&J) Vaccinations
THE FDA & CDC have recommended a pause in administering J&J (Janssen) COVID vaccinations after the VAERS (Vaccine Adverse Event Reporting System) had reports of six (6) women, between the ages of 18 and 48, developing a rare type of blood clot between 6 & 13 days after receiving the J&J vaccine. This article contains an overview of the HAN Alert Recommendation and why it is so important, some information about this rare clot, adenovirus- vector COVID vaccines, a chart comparing CVST stats in different groups, and the limited causation evidence between the J&J vaccine and this rare type of clot. Lastly, it contains information on what First Responders can do, regarding the information, and tis application to patient and personal management.
There is also a link to Resources & Links for more detailed information on the subject from a variety of sources & formats. They are divided into categories and are labelled.
